RxDoctor Payments Data

Jacqueline Romero, DO

Family Medicine · Naples, FLNPI 1023041761

Payments from drug & device makers

$2,077in general payments, 2019–2025

Across 74 payments — averaging $28.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merz North America, Inc.$504
  • Inspire Medical Systems, Inc.$196
  • Amgen$196
  • Galderma Laboratories, L.p.$194
  • Esperion Therapeutics, Inc.$146
  • Novartis$135
  • plus $707 from 13 others

What the payments were for

  • Food & beverage$2,077100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,077 in reported general payments places this provider in the 75th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$118,654
Medicare patients
193
Services billed
1,878

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide19$27,319
EliquisApixaban22$26,983
Repatha SureclickEvolocumab27$22,166
JanuviaSitagliptin Phosphate14$14,399
OzempicSemaglutide11$13,371
Trelegy ElliptaFluticasone/Umeclidin/Vilanter14$8,880
Colesevelam Hcl19$3,878
SynthroidLevothyroxine Sodium29$3,262
Estradiol (Twice Weekly)Estradiol21$2,877
Ezetimibe60$1,517
Memantine Hcl ErMemantine Hcl12$1,237
Testosterone Cypionate13$1,012
Atorvastatin Calcium121$1,006
Levothyroxine Sodium89$967
Raloxifene Hcl20$931

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$61$27,31919 claims
PfizerEliquis$38$26,98322 claims
Novo NordiskOzempic$71$13,37111 claims
GSKTrelegy Ellipta$128$8,88014 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Naples

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →